Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

GenVec Inc (GNVC)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow GenVec's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
GenVec historical data, for real-time data please try another search
7.1930 0.0000    0.00%
16/06 - Real-time Cboe. Currency in USD ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 7.0101 - 7.2500
Type:  Equity
Market:  United States
GenVec 7.1930 0.0000 0.00%

GenVec Inc Company Profile

 
Get an in-depth profile of GenVec Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

15

Equity Type

ORD

GenVec, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of therapeutics and vaccines through its proprietary AdenoVerse gene delivery platform in the United States. It designs, tests, and manufactures adenoviral-based product candidates. The company’s lead product candidate is CGF166, which is in Phase I/II clinical trial for the treatment of hearing loss and balance disorders. It is also developing GV2311 vaccine for respiratory syncytial virus; and GV2207 vaccine for the treatment of herpes simplex virus. The company has a collaboration agreement with Novartis AG to develop CGF166. It also has collaboration agreement with TheraBiologics, Inc. to develop cancer therapeutics; National Institute of Allergy and Infectious Diseases to generate vaccine candidates for the prevention of malaria; Laboratory of Malaria Immunology and Vaccinology to create and test various malaria vaccine candidates; and Merial to develop and commercialize vaccine and anti-viral candidates for the prevention and containment of foot-and-mouth diseases in livestock and other animals. The company was founded in 1992 and is based in Gaithersburg, Maryland. GenVec, Inc. operates as a subsidiary of Precigen, Inc.

Contact Information

Address 910 Clopper Road Suite 220N
Gaithersburg, 20878
United States
Phone 240-632-0740
Fax 240-632-0735
Web www.genvec.com
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

GNVC Comments

Write your thoughts about GenVec Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email